Prosecution Insights
Last updated: November 04, 2026
Application No. 18/618,970

Lactoferrin Polypeptide Fragment, Preparation Method Thereof, Antibody Prepared Using the Same, and Applications

Non-Final OA §101§102§112
Filed
Mar 27, 2024
Examiner
NGUYEN, NAM P
Art Unit
1678
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Beijing Biosynthesis Biotechnology Co. Ltd.
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
187 granted / 341 resolved
-5.2% vs TC avg
Strong +49% interview lift
Without
With
+48.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
50 currently pending
Career history
397
Total Applications
across all art units

Statute-Specific Performance

§101
4.9%
-35.1% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 341 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Status of Claims Claims 1-17 are pending. Claims 2-13 and 17 are withdrawn. Claims 1 and 14-16 are under examination. Election/Restrictions Applicant's election with traverse of Group I (claims 1 and 14-16) in the reply filed on 09/10/2026 is acknowledged. The traversal is on the ground(s) that claim 17 should be rejoined because claim 14 recites anti-Lactoferrin antibody prepared using the lactoferrin polypeptide fragment and claim 17 is the use of the lactoferrin polypeptide fragment of claim 1 in the preparation fragment of claim 1. Applicant also argues that there is no search burden. This is not found persuasive because using a peptide fragment for assaying has different functional and structural characteristics (i.e., materially different process) than an antibody for lactoferrin. As stated in the Restriction (bottom of page 3), Group I focuses on searching the structure of product rather the process of using it. Meanwhile, the withdrawn claim 17 could be part of “use” claims which is an attempt to claim a process without setting forth active steps which could be under 35 U.S.C. 101. In other words, the claim is not for rejoinder if the product were to be found allowable. The requirement is still deemed proper and is therefore made FINAL. Claims 2-13 and 17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1 and 14-16 are rejected under 35 U.S.C. 101 because the claimed invention is directed to natural product without significantly more. Claim 1 recites a lactoferrin polypeptide fragment that has an amino acid sequence shown in SEQ ID NO: 1. Claims 14-16 recite an anti-lactoferrin antibody. With respect to claim 1, Cornish teaches lactoferrin fragment is natural (at para. [0056]). Cornish teaches peptide fragments that contain KNLL (651-659 residues) and FNDNTECL (660-668 residues) (at Table 1b-continued, right col. of pg. 13). Cornish also teaches SEQ ID NO:8 (see below) which contains the claimed Lactoferrin polypeptide fragment that has the full-length of SEQ ID NO: 1 (US2009/0270309A1, published 10/29/2009). With respect to claims 14-16, Audrain teaches anti-lactoferrin autoantibodies are found in several autoimmune conditions (at abstract) (“Anti-Lactoferrin Autoantibodies: Relation between Epitopes and Iron-binding Domain”, Journal of Autoimmunity (1996), vol. 9, pgs. 569-574). The claimed lactoferrin fragment is analyzed to determine if separating a peptide from its surrounding material has resulted in having different characteristics from its naturally occurring counterpart. Based on the limited background information, there is no indication that separating into a peptide fragment (as claimed) has any characteristics (structural, functional, or otherwise) that are different from naturally occurring fragments hydrolyzed, for example, by protease enzymes in the body. Also, SEQ ID NO: 8 of Cornish is from a natural Bos taurus (cattle). The claim therefore encompasses a sequence that is structurally and functionally identical to naturally occurring sequence/protein. Additionally, the structure of Audrain’s anti-lactoferrin autoantibodies is the same as the claimed anti-lactoferrin antibody (both structures bind to lactoferrin). Because there is no difference between the claimed and naturally occurring structures, the claimed peptide fragment and antibody do not have markedly different characteristics from what occurs in nature, and thus is a “product of nature” exception. Accordingly, the claim is directed to an exception (Step 2A: YES). Because the claim does not include any additional features that could add significantly more to the exception (Step 2B: NO), the claims do not qualify as eligible subject matter and being rejected under 35 U.S.C. § 101. With respect to claims 15-16, these recitations are directed to the product-by-process (see below). Thus, these limitations do not change the structure of the claimed antibody of claim 14. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 15-16 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 15-16 recite recitations that are directed to “product-by-process” claim of producing the anti-lactoferrin antibody. However, these product-by-process recitations do not further limit the structure of the anti-lactoferrin antibody other than defining the steps of producing the antibody. The structure of the anti-lactoferrin antibody has not changed, therefore, these recitations do not further limit the structure of the product of claim 14. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Cornish et al. (US2009/0270309A1, published 10/29/2009). Cornish teaches lactoferrin fragment or a lactoferrin hydrolysate (see abstract). Cornish teaches peptide fragments that contain KNLL (651-659 residues) and FNDNTECL (660-668 residues) (at Table 1b-continued, right col. of pg. 13), which would read on an amino acid sequence shown in SEQ ID NO: 1). The phrase “an amino acid sequence shown in SEQ ID NO: 1” encompasses sequences that comprise the full-length sequence of SEQ ID NO:1 or any portion of SEQ ID NO: 1. On the other hand, if the phrase were to recite “the amino acid sequence shown in SEQ ID NO: 1”, then the claim encompasses only the full length of SEQ ID NO: 1, with or without additional amino acid residues at either or both ends. However, Cornish also teaches SEQ ID NO:8 (see below) which contains the claimed Lactoferrin polypeptide fragment that has the full-length of SEQ ID NO: 1. PNG media_image1.png 584 734 media_image1.png Greyscale Claim 14-16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Keiichi et al. (JPH08269099A, published 10/15/1996). The passages cited below are from a machine translation, as Keiichi is not in English. Keiichi teaches peptide of a human or bovine source lactoferrin fragment with sensitivity (see abstract). Keiichi teaches an anti-lactoferrin polyclonal antibody (at pg. 3, para. 2), which would read on the structure of an anti-lactoferrin antibody. Keiichi teaches a peptide derived from human lactoferrin to produce the monoclonal antibody (at pg. 3, para. 5). Note that the recitation of “prepared using the lactoferrin polypeptide fragment” is interpreted as product-by-process of a product claim because the recitation does not set forth a process. The recitation of “prepared using the Lactoferrin polypeptide fragment according to claim 1, wherein the anti-Lactoferrin antibody is prepared by: coupling the Lactoferrin polypeptide fragment to a carrier protein, conducting rabbit immunization, collecting rabbit blood when a specific immunoglobulin (IgG) concentration in a rabbit serum reaches a peak, and then separating and purifying the rabbit serum for the anti-Lactoferrin antibody” is product-by-process limitation. The claim is directed to a product which is an anti-Lactoferrin antibody. Thus, Keiichi’s anti-lactoferrin polyclonal antibody reads on all the structures of the claimed antibody. MPEP 2113 states: “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted) (Claim was directed to a novolac color developer. The process of making the developer was allowed. The difference between the inventive process and the prior art was the addition of metal oxide and carboxylic acid as separate ingredients instead of adding the more expensive pre-reacted metal carboxylate. The product-by-process claim was rejected because the end product, in both the prior art and the allowed process, ends up containing metal carboxylate. The fact that the metal carboxylate is not directly added, but is instead produced in-situ does not change the end product.). Furthermore, "[b]ecause validity is determined based on the requirements of patentability, a patent is invalid if a product made by the process recited in a product-by-process claim is anticipated by or obvious from prior art products, even if those prior art products are made by different processes." Amgen Inc. v. F. Hoffman-La Roche Ltd., 580 F.3d 1340, 1370 n 14, 92 USPQ2d 1289, 1312, n 14 (Fed. Cir. 2009). However, in the context of an infringement analysis, a product-by-process claim is only infringed by a product made by the process recited in the claim. Id. at 1370 ("a product in the prior art made by a different process can anticipate a product-by-process claim, but an accused product made by a different process cannot infringe a product-by-process claim"). (Emphasis added). With respect to claims 15-16, these recitations are directed to the product-by-process (see above). Thus, these limitations do not change the structure of the claimed antibody of claim 14. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NAM P NGUYEN whose telephone number is (571)270-0287. The examiner can normally be reached Monday-Friday (8-4). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at (571)272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.P.N/Examiner, Art Unit 1678 /SHAFIQUL HAQ/Primary Examiner, Art Unit 1678
Read full office action

Prosecution Timeline

Mar 27, 2024
Application Filed
Oct 01, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782345
ADDITIVE, SURFACE TREATMENT AGENT, SURFACE-MODIFIED LATEX PARTICLES, METHOD FOR PRODUCING SURFACE-MODIFIED LATEX PARTICLES, REAGENT FOR LATEX AGGLUTINATION REACTION, KIT, AND METHOD FOR DETECTING TARGET SUBSTANCE
4y 3m to grant Granted Nov 03, 2026
Patent 12753235
FC-BINDING PROTEIN HAVING IMPROVED ACID STABILITY, PRODUCTION METHOD FOR SAID PROTEIN, AND ANTIBODY-ADSORBING AGENT USING SAID PROTEIN
6y 1m to grant Granted Oct 06, 2026
Patent 12742774
METHODS FOR DETECTING ABERRANT RESULTS CAUSED BY INCOMPLETE DELIVERY OF A POLYHAPTEN REAGENT IN IMMUNOASSAYS
4y 11m to grant Granted Sep 22, 2026
Patent 12730109
TARGETED SIALIC ACID LABELING COMPOUNDS, METHODS, AND USES THEREOF
5y 4m to grant Granted Sep 08, 2026
Patent 12724033
CHEMILUMINESCENT COMPOUNDS FOR MULTIPLEXING
4y 7m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+48.7%)
3y 8m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 341 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month